BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Altered expression of type-1 and type-2 cannabinoid receptors in celiac disease.
Authors: Natalia Battista, Antonio Di Sabatino, Monia Di Tommaso, Paolo Biancheri, Cinzia Rapino, et al
PLoS One, 19 April 2013
—
Anandamide (AEA) is the prominent member of the endocannabinoid family and its biological action is mediated through the binding to both type-1 (CB1) and type-2 (CB2) cannabinoid receptors (CBR). The presence of AEA and CBR in the gastrointestinal tract highlighted their patho…
Does using marijuana increase the risk for developing schizophrenia?
Authors: A. Eden Evins, Alan I. Green, John M. Kane, Sir Robin M. Murray
The Journal of Clinical Psychiatry, April 2013
—
As more US states and other countries consider legalizing marijuana, clinicians need to know the possible effects of this drug. Research has shown a connection between marijuana use and an increased risk for schizophrenia in young people who are vulnerable to developing psycho…
Prenatal substance abuse: short- and long-term effects on the exposed fetus.
Authors: Marylou Behnke, Vincent C. Smith, COMMITTEE ON SUBSTANCE ABUSE, COMMITTEE ON FETUS AND NEWBORN
Pediatrics, March 2013
—
Prenatal substance abuse continues to be a significant problem in this country and poses important health risks for the developing fetus. The primary care pediatrician’s role in addressing prenatal substance exposure includes prevention, identification of exposure, recognition…
Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
Authors: Javier Fernández‐Ruiz, Onintza Sagredo, M. Ruth Pazos, Concepción García, Roger Pertwee, et al
British Journal of Clinical Pharmacology, February 2013
—
Cannabidiol (CBD) is a phytocannabinoid with therapeutic properties for numerous disorders exerted through molecular mechanisms that are yet to be completely identified. CBD acts in some experimental models as an anti-inflammatory, anticonvulsant, anti-oxidant, anti-emetic, an…
Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results.
Authors: Sunil Aggarwal
Clinical Journal of Pain, February 2013
—
OBJECTIVES: This article attempts to cover pragmatic clinical considerations involved in the use of cannabinergic medicines in pain practice, including geographical and historical considerations, pharmacokinetics, pharmacodynamics, adverse effects, drug interactions, indicatio…
Role of Cannabinoids in Pain Management
Authors: Ethan B. Russo, Andrea G. Hohmann
Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches, 2013
—
It is a curious fact that we owe a great deal of our insight into pharmacological treatment of pain to the plant world. Willow bark from Salix spp. led to development of aspirin and eventual elucidation of the analgesic effects of prostaglandins and their role in inflammation…
The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients on supportive or palliative care.
Authors: Gil Bar-Sela, Marina Vorobeichik, Saher Drawsheh, Anat Omer, Victoria Goldberg, Ella Muller
Evidence-Based Complementary and Alternative Medicine, 2013
—
BACKGROUND: Cancer patients using cannabis report better influence from the plant extract than from synthetic products. However, almost all the research conducted to date has been performed with synthetic products. We followed patients with a medicinal cannabis license to eval…
Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.
Authors: Alysia N. Lozano‐Ondoua, Katherine E. Hanlon, Ashley M. Symons‐Liguori, et al
Journal of Bone and Mineral Research, January 2013
—
Most commonly originating from breast malignancies, metastatic bone cancer causes bone destruction and severe pain. Although novel chemotherapeutic agents have increased life expectancy, patients are experiencing higher incidences of fracture, pain, and drug-induced side effec…
The endocannabinoid system in normal and pathological brain ageing.
Authors: Andras Bilkei-Gorzo
Philosophical Transactions of the Royal Society B: Biological Sciences, 5 December 2012
—
The role of endocannabinoids as inhibitory retrograde transmitters is now widely known and intensively studied. However, endocannabinoids also influence neuronal activity by exerting neuroprotective effects and regulating glial responses. This review centres around this less-s…
Lower levels of cannabinoid 1 receptor mRNA in female eating disorder patients: association with wrist cutting as impulsive self-injurious behavior.
Authors: Marc Schroeder, Christian Eberlein, Martina de Zwaan, Johannes Kornhuber, Stefan Bleich, Helge Frieling
Psychoneuroendocrinology, December 2012
—
The cannabinoid 1 (CB 1) receptor as the primary mediator of the endocannabinoid (EC) system was found to play a role in eating disorders (EDs), depression, anxiety, and suicidal behavior. The CB 1 receptor is assumed to play a crucial role in the central reward circuitry with…
The molecular connections between the cannabinoid system and endometriosis.
Authors: A.M. Sanchez, P. Vigano, A. Mugione, P. Panina-Bordignon, M. Candiani
Molecular Human Reproduction, December 2012
—
The endocannabinoid system consists of an array of endogenously produced bioactive lipids that activate cannabinoid 1 (CB1) and 2 (CB2) receptors. Alterations of this system have been described in almost every category of disease. These changes can be protective or maladaptive…
Multiple sclerosis and extract of cannabis: results of the MUSEC trial.
Authors: John Peter Zajicek, Jeremy C. Hobart, Anita Slade, David Barnes, Paul G. Mattison
Journal of Neurology, Neurosurgery, & Psychiatry, November 2012
—
OBJECTIVE: Multiple sclerosis (MS) is associated with chronic symptoms, including muscle stiffness, spasms, pain and insomnia. Here we report the results of the Multiple Sclerosis and Extract of Cannabis (MUSEC) study that aimed to substantiate the patient based findings of pr…